Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 6,187 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Medication Group Clear all

Conditions: Acute Pain, Headache, Musculoskeletal Pain
Interventions: Usual Care/Guideline, Opioid Justification, Provider Comparison; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 22,616 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Zika Virus, Zika Virus Infection, Virus Diseases, Flavivirus Infections, Flaviviral Diseases, Flaviviridae Infections, RNA Virus Infections
Interventions: VRC-ZKADNA090-00-VP, VRC-PBSPLA043-00-VP; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 15 Years to 35 Years
Enrollment: 2,428 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Miami, Florida • Edinburg, Texas • Houston, Texas

Conditions: Anxiety Disorder Social, Anxiety
Interventions: botulinum toxin A, Placebo; Drug · Other
Lead sponsor: Daniel Lieberman; Other
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: X-linked Retinoschisis, XLRS
Interventions: Dorzolamide 2% TID or brinzolamide 1% TID; Drug
Lead sponsor: Beacon Therapeutics; Industry
Eligibility: 7 Years and older · Male only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 3
States / cities: Ann Arbor, Michigan • Portland, Oregon • Dallas, Texas

Conditions: Healthy
Interventions: Clopidogrel, Placebo, Pantoprazole; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Psychotic Disorders
Interventions: Electronic Screen + Education (Phase 1), Targeted Provider Education (Phase 1), Community Mobile Engagement (Phase 2), Clinic based Engagement (Phase 2); Other
Lead sponsor: University of California, Davis; Other
Eligibility: 12 Years to 30 Years
Enrollment: 427 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Acute Coronary Syndrome, Angioplasty, Transluminal, Percutaneous Coronary, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Blood Platelets
Interventions: rosuvastatin, placebo; Drug
Lead sponsor: Susan Smyth; Other
Eligibility: 18 Years to 80 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Post-Lung Transplantation
Interventions: Coping Skills Training combined with Exercise (CSTEX), Standard of Care plus Education (SOC-ED); Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Chronic Pain
Interventions: GetActive-Fitbit, Healthy Living for Pain; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Chicago, Illinois • Boston, Massachusetts • Durham, North Carolina

Conditions: Opioid-use Disorder, Addiction, Depression, Post-traumatic Stress Disorder
Interventions: Collaborative Care; Behavioral
Lead sponsor: RAND; Other
Eligibility: 18 Years and older
Enrollment: 729 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 16
States / cities: Los Angeles, California • Santa Monica, California • Albuquerque, New Mexico + 5 more

Conditions: Asthma
Interventions: SAR440340, Dupilumab, Fluticasone or Fluticasone/salmeterol combination, Placebo for SAR440340, Placebo for dupilumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 18
States / cities: Birmingham, Alabama • Long Beach, California • Los Angeles, California + 14 more

Conditions: BPH With Urinary Obstruction, BPH, Hematuria, Same Day Discharge
Interventions: Furosemide; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 89 Years · Male only
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Primary Pulmonary Hypertension
Interventions: LIQ861 Inhaled Treprostinil; Drug
Lead sponsor: Liquidia Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 38
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 30 more

Conditions: Obesity, Weight Loss, CHD - Coronary Heart Disease
Interventions: Exercise, Health Education, Exercise Compliance, Calorie-Restricted Diet, Behavioral Modification, Weight-Loss Compliance, Dietary Counseling; Other · Behavioral · Dietary Supplement
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 40 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Cystic Fibrosis Related Bone Disease
Interventions: Estradiol 2 mg, Placebo; Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Acne Vulgaris
Interventions: GDC 268 Lotion, Clindamycin Phosphate Lotion 1%, GDC Vehicle Lotion; Drug
Lead sponsor: Balmoral Medical company; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 1,236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 34
States / cities: Fort Smith, Arkansas • Rogers, Arkansas • Fountain Valley, California + 31 more

Conditions: Hypertension, Metabolic Syndrome
Interventions: Aliskerin/Valsartan and Rampiril; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Opioid Abuse, Opioid Dependence, Opioid-Related Disorders, Opioid Use
Interventions: Lorcaserin, Placebo; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Smoking Cessation
Interventions: Contingency management, Nicotine replacement therapy, Varenicline, Additional behavioral support; Behavioral · Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hepatitis C, HIV Infections, Opioid-use Disorder
Interventions: PRC brief motivational interview intervention, Phone contact; Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Stem Cell Transplant
Interventions: Standard of Care - Observation Only, Group 2: Quercetin, Group 2: Dasatinib; Other · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: COPD Exacerbation Acute
Interventions: CUVITRU - Ig subcutaneous human 20%, Standard Medical Therapy; Biological · Other
Lead sponsor: Rochester General Hospital; Other
Eligibility: 18 Years to 82 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Rochester, New York

Conditions: GERD (Gastroesophageal Reflux Disease)
Interventions: Fortiskap; Device
Lead sponsor: Cosmos Rx, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Salisbury, Maryland

Conditions: Depression, Opioid-use Disorder, Opioid Abuse
Interventions: Ketamine Hydrochloride, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Charleston, South Carolina

Search by objective public record fields.

Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care

VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents

A Study of the Efficacy of Botox in the Treatment of Social Anxiety Disorder

Clinical Evaluation of Patients With X-linked Retinoschisis

Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Pantoprazole 80 mg in Healthy Subjects

Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement

Early Use of Rosuvastatin in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions

Improving Lung Transplant Outcomes With Coping Skills and Physical Activity

The Thrive Study: Improving Multimodal Physical Function in Adults With Heterogenous Chronic Pain

Collaboration Leading to Addiction Treatment and Recovery From Other Stresses

Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants

Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP

Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil

Targeting Obesity to Optimize Health in Cardiac Rehab (TOPCARE)

Pilot E2 for Hypogonadal Women With CFBD

Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris

The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome

Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder

A Smoking Cessation Intervention for Yale Dining Employees

Coaching for HCV and HIV

Hematopoietic Stem Cell Transplant Survivors Study

Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, and the Effect of SCIgR for Prevention

A Comparison of Cosmos Rx Medication Adherence Platform vs. Pharmacy Fill Adherence Measures

Ketamine for the Treatment of Opioid Use Disorder and Depression